tiprankstipranks
Vaccitech cancer vaccine ‘shows promise’ in animal studies, NIH researchers say
The Fly

Vaccitech cancer vaccine ‘shows promise’ in animal studies, NIH researchers say

An experimental therapeutic cancer vaccine, SNAPvax, designed by Robert Seder, M.D., and colleagues at the NIAID Vaccine Research Center together with collaborators from Vaccitech North America, induced "two distinct and desirable immune system responses that led to significant tumor regression in mice," report investigators from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Vaccitech has announced plans to advance the SNAPvax platform for use in treating human papilloma virus-associated cancer in 2023, the NIH report noted. Reference Link

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on VACC:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles